Cargando…

Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018

IMPORTANCE: Drug companies frequently claim that high prices are needed to recoup spending on research and development. If high research and development costs justified high drug prices, then an association between these 2 measures would be expected. OBJECTIVE: To examine the association between tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wouters, Olivier J., Berenbrok, Lucas A., He, Meiqi, Li, Yihan, Hernandez, Inmaculada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513642/ https://www.ncbi.nlm.nih.gov/pubmed/36156148 http://dx.doi.org/10.1001/jamanetworkopen.2022.18623

Ejemplares similares

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Evaluation of Frequency of Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among Medicare Beneficiaries
por: Berenbrok, Lucas A., et al.
Publicado: (2020)

Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
por: Tay-Teo, Kiu, et al.
Publicado: (2019)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
por: Grischott, Thomas
Publicado: (2020)

Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018
por: Wouters, Olivier J.
Publicado: (2020)

Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019
por: Galkina Cleary, Ekaterina, et al.
Publicado: (2023)

Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries
por: Hernandez, Inmaculada, et al.
Publicado: (2018)

Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease
por: San-Juan-Rodriguez, Alvaro, et al.
Publicado: (2019)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
por: Peet, Evan D., et al.
Publicado: (2022)

Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018
por: Asbell, Penny A., et al.
Publicado: (2020)

National Trends in the Safety Performance of Electronic Health Record Systems From 2009 to 2018
por: Classen, David C., et al.
Publicado: (2020)

Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
por: Mousavi, Idine, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Trends in International Cancer Research Investment 2006-2018
por: Abudu, Rachel, et al.
Publicado: (2021)

How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
por: Lexchin, Joel
Publicado: (2014)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018
por: Wallach, Joshua D., et al.
Publicado: (2021)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
por: Benjamin, David J., et al.
Publicado: (2022)

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Association of Private Equity Investment in US Nursing Homes With the Quality and Cost of Care for Long-Stay Residents
por: Braun, Robert Tyler, et al.
Publicado: (2021)

Assessment of Opioid Prescribing Patterns in a Large Network of US Community Health Centers, 2009 to 2018
por: Muench, John, et al.
Publicado: (2020)

Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs
por: Miller, Jennifer E., et al.
Publicado: (2021)

Return on Investment: A Fuller Assessment of the Benefits and Cost Savings of the US Publicly Funded Family Planning Program
por: Frost, Jennifer J, et al.
Publicado: (2014)

Trends in Racial and Ethnic Disparities in the Receipt of Lifesaving Procedures for Hospitalized Patients With Decompensated Cirrhosis in the US, 2009-2018
por: Nephew, Lauren D., et al.
Publicado: (2023)

Cost of healthy and culturally acceptable diets in Brazil in 2009 and 2018
por: Verly, Eliseu, et al.
Publicado: (2021)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry
por: Zhou, Edward W., et al.
Publicado: (2023)

Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results
por: Rennane, Stephanie, et al.
Publicado: (2022)

Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
por: Yeung, Kai, et al.
Publicado: (2021)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3b0rflp3pl3vu9cjmhrtktk8ef